Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 27, 2019 16:05 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Attendance at Citi’s 14th Annual Biotech Conference

PITTSBURGH, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients...
August 05, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Reports Second Quarter 2019 Financial and Operating Results

FDA grants RMAT designation for KB103 to treat dystrophic epidermolysis bullosa (DEB) Announced positive results from Phase 2 trial (“GEM-2”) of KB103 Submitted an IND application to initiate a...
July 01, 2019 09:05 ET | Source: Krystal Biotech, Inc.

Krystal Biotech, Inc. Added to the Russell 2000 Index

PITTSBURGH, July 01, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat skin diseases, today announces that it has been...
June 24, 2019 19:49 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Pricing of $100.0 Million Public Offering of Common Stock

PITTSBURGH, June 24, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients...
June 24, 2019 16:47 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Proposed $100 Million Public Offering of Common Stock

PITTSBURGH, June 24, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients...
June 24, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial (“GEM-2 study”) of KB103 and Receives Regenerative Medicine Advanced Therapy (“RMAT”) Designation from FDA for KB103

Safety data from all patients show that KB103 was well tolerated with no adverse events reportedFive out of six wounds treated with KB103 in the Phase 2 trial closed 100% during the trialThe average...
June 14, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Submits Investigational New Drug (IND) Application for KB105, Topical Gene Therapy Candidate for Transglutaminase-1 Deficient Autosomal Recessive Congenital Ichthyosis

KB105 is a new gene therapy candidate engineered with a Transglutaminase-1 (TGM1) gene construct to treat TGM1 deficient autosomal recessive congenital ichthyosis KB105 is the second pipeline product...
May 15, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech to Present at the RBC Capital Markets 2019 Healthcare Conference

PITTSBURGH, May 15, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat dermatological diseases, today announced that...
May 06, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Reports First Quarter 2019 Financial Results and Provides Corporate Update

EMA grants PRIME eligibility for KB103 (bercolagene telserpavec) to treat dystrophic epidermolysis bullosa Krystal Biotech announces five presentations of clinical and preclinical data at the...
April 29, 2019 08:00 ET | Source: Krystal Biotech, Inc.

Krystal Biotech Announces Five Presentations of Clinical and Preclinical Data at the Society for Investigative Dermatology Annual Meeting

PITTSBURGH, April 29, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases announces presentations of...